Novel approaches for reducing free light chains in patients with myeloma kidney.

Colin Hutchison, J Bladé, Paul Cockwell, M Cook, Mark Drayson, JP Fermand, E Kastritis, R Kyle, Newman Leung, S Pasquali, C Winearls

Research output: Contribution to journalArticle

23 Citations (Scopus)


Myeloma kidney is a tubulointerstitial pathology that accounts for approximately 80-90% of severe acute kidney injury in patients with multiple myeloma. Unless there is rapid intervention, progressive irreversible damage from interstitial fibrosis and tubular atrophy occurs. Work over the past decade has demonstrated that an early sustained reduction in serum concentrations of pathogenic monoclonal free light chains (FLCs) leads to improved renal recovery rates. In turn, an early improvement in renal function is associated with improved patient survival. An early reduction in FLC levels should therefore become standard of care, although the optimum mechanisms to achieve this depletion of FLCs remain to be determined. To provide a coordinated, cross-disciplinary approach to research in this disease, the International Kidney and Monoclonal Gammopathy Research Group was formed. In this Review, we address the current state of knowledge in the management of myeloma kidney.
Original languageEnglish
JournalNature Reviews. Nephrology
Publication statusPublished - 21 Feb 2012


Dive into the research topics of 'Novel approaches for reducing free light chains in patients with myeloma kidney.'. Together they form a unique fingerprint.

Cite this